16:22 , Mar 28, 2019 |  BC Extra  |  Clinical News

Seattle Genetics, Astellas ADC heading for bladder cancer submission

Seattle Genetics and Astellas plan to seek accelerated approval of antibody-drug conjugate enfortumab vedotin based on data from the pivotal Phase II EV-201 trial to treat bladder cancer. Interim results showed that among 128 patients...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
21:50 , Feb 8, 2019 |  BC Extra  |  Company News

Seattle Genetics down on light 2019 Adcetris sales guidance

Seattle Genetics Inc. (NASDAQ:SGEN) fell $8.73 (12%) to $65.02 Friday after announcing late Thursday 2019 guidance for Adcetris brentuximab vedotin sales below the consensus estimate. The move represents a market cap loss of almost $1.4...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Enfortumab vedotin: Phase I data

An open-label, dose-escalation, North American Phase I trial in 28 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin showed that once-weekly 0.5, 0.75, 1 and...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Seattle Genetics, Abbott, Astellas, Pfizer deal

Seattle Genetics disclosed in its 4Q11 earnings that it received undisclosed milestone payments from Abbott and Pfizer under separate 2011 deals granting the pharmas rights to use Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Company News

Seattle Genetics, Astellas deal

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-22ME . Agensys submitted an IND last quarter for a Phase I trial of the antibody-drug conjugate (ADC) targeting nectin-4...